Your session is about to expire
← Back to Search
Zilovertamab vedotin for Waldenstrom Macroglobulinemia
Study Summary
This trial is studying zilovertamab vedotin to see how well it works in treating patients with hematological cancers that have come back or have not responded to previous treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a type of blood cancer that has been treated in the past but has gotten worse or come back after treatment.You currently need medical treatment because of symptoms or complications caused by your disease, low blood cell counts, enlarged lymph nodes or organs, involvement of organs outside of lymph nodes, or your disease is getting worse over time.You have had a serious heart condition in the last 3 months before starting the study treatment.You have already received treatment with a specific type of medication called a ROR1-directed therapy.You have taken a medication within the past week that can make your heart rhythm abnormal.You are eligible for a special type of treatment called hematopoietic stem cell transplantation (HSCT) or chimeric antigen receptor (CAR)-T-cell therapy. You have access to these treatments and are willing to undergo them.You have another type of cancer that could make it unsafe or difficult to participate in the study, or could affect how the study results are interpreted.If you have a type of blood cancer that is unlikely to respond to current treatments or if you have had bad reactions to previous treatments that are known to be effective.You have been treated with a medication that contains MMAE before, and that's okay.
- Group 1: Zilovertamab vedotin Schedule 3: Q3/4W
- Group 2: Zilovertamab vedotin Schedule 1: Q1/3W
- Group 3: Zilovertamab vedotin Schedule 2: Q2/3W
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA authorized Zilovertamab vedotin for public use?
"The safety rating of Zilovertamab vedotin is assessed as a 1 due to the limited clinical evidence available from Phase 1 trials."
How many research centers are conducting the trial?
"Patients can participate in this clinical trial at Swedish Medical Center (Site 0002) located in Seattle, Washington; City of Hope National Medical Centre situated in Duarte, Texas; and UC San Diego Moores Cancer Centre based out of Los Angeles, Virginia. Additionally there are 24 other sites recruiting patients for the study."
What projected effects are researchers seeking to achieve through this research?
"As disclosed by the trial sponsor, VelosBio Inc., the primary outcome evaluated over a 21-day period is Maximum Tolerated Dose (MTD) of VLS-101. Secondary outcomes being analyzed include tumour response based on established criteria, average number of infusions administered as per prescription records and clearance levels in blood samples before and after drug administration."
Are there any available spots in this research investigation for participants?
"As per the clinicaltrials.gov portal, this trial is not currently enrolling patients as of October 11th 2022. Initially posted on March 14th 2019 and last updated at that same date, there are 3,054 other trials actively recruiting right now."
Share this study with friends
Copy Link
Messenger